Yes there is not much value in a drug with only cardioprotection, but a drug with broad anticancer activity that is cardioprotective is very valuable. This is explained in detail in the Triangle report.
These drug that were sold off by Clinigen are all generics - the margins on generics are very low and the competition intense.
Yes there is not much value in a drug with only...
-
- There are more pages in this discussion • 1,522 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
-0.088(5.01%) |
Mkt cap ! $285.2M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.62 | $238.8K | 141.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19025 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 2500 | 1 |
View Market Depth
| Last trade - 15.40pm 03/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |